<DOC>
	<DOCNO>NCT01246804</DOCNO>
	<brief_summary>The objective study evaluate effect ginkgo biloba ( steady state ) pharmacokinetics single dose UGT-substrate raltegravir . Furthermore safety profile combination study .</brief_summary>
	<brief_title>The Influence GINkGo Biloba Pharmacokinetics UGT Substrate raltEgraviR ( GINGER )</brief_title>
	<detailed_description>Ginkgo biloba alternative medicine popular among HIV-infected patient claim positive effect memory , concentration depression . Alternative medicine cause drug-drug interaction regular HIV-medication . Raltegravir newly develop HIV integrase inhibitor . It metabolize liver UGT1A1 therefore pharmacokinetic profile influence inhibitor inducer UGT1A1 . So far data potential effect ginkgo biloba glucuronidation vivo . The current study design evaluate potential inductive effect ginkgo biloba pharmacokinetics raltegravir safety profile use combination .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Subject least 18 old 55 year screen . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior first dose Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . Subject able willing sign Informed Consent Form prior screen evaluation . Subject good ageappropriate health condition establish medical history , physical examination , electrocardiography , result biochemistry , haematology urinalysis test within 4 week prior Day 1 . Results biochemistry , haematology urinalysis test within laboratory 's reference range . If laboratory result within reference range , subject include condition Investigator judge deviation clinically relevant . This clearly record . Subject normal blood pressure pulse rate , accord Investigator 's judgement . Documented history sensitivity/idiosyncrasy medicinal product excipients . Positive HIV test . Positive hepatitis B C test . Pregnant female ( confirm HCG test perform less 4 week Day 1 ) breastfeed female . Female subject childbearing potential without adequate contraception , e.g . hysterectomy , bilateral tubal ligation , ( nonhormonal ) intrauterine device , total abstinence , double barrier method , two year postmenopausal . They must agree take precaution order prevent pregnancy throughout entire conduct trial . Therapy drug ( two week precede dose ) , except paracetamol . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , psychiatric disorder , gastrointestinal disorder , renal hepatic disorder , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . History current abuse drug , alcohol solvent . Inability understand nature extent trial procedure require . Participation drug trial within 60 day prior Day 1 . Donation blood within 60 day prior Day 1 . Febrile illness within 3 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>interaction</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>